Top Buy Stocks
Sign In
Invest in ACST
$3.37
+0 (+0%)
At Close: Jan 24, 2025
Acasti Announces Corporate Name Change to Grace Therapeutics, Inc.
08:00am, Friday, 25'th Oct 2024
Name Change Reflects Extensive Scientific and Corporate Brand Equity Previously Established under Grace Therapeutics Grace Therapeutics will begin trading on Nasdaq under the trading symbol "GRCE" eff
Acasti Announces Completion of Patient Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial of GTX-104
07:30am, Wednesday, 25'th Sep 2024
Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025 Data Readout Expected Early Calendar 2025; NDA Submission on Track for 1H Calendar 2025
Acasti to Participate in the H.C. Wainwright 26th Annual Global Investment Conference
10:35am, Thursday, 05'th Sep 2024
PRINCETON, N.J., Sept. 05, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of ni
Acasti Announces First Fiscal Quarter 2025 Financial Results, Provides Business Update
08:00am, Friday, 09'th Aug 2024
PRINCETON, N.J., Aug. 09, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of nim
Is Acasti Pharma (ACST) Outperforming Other Medical Stocks This Year?
10:41am, Wednesday, 10'th Jul 2024
Here is how Acasti Pharma (ACST) and Cigna (CI) have performed compared to their sector so far this year.
Acasti Announces Achievement of 50% Enrollment in Pivotal Phase 3 STRIVE-ON Safety Trial
04:05pm, Thursday, 27'th Jun 2024
Company Anticipates Completion of Patient Enrollment in the STRIVE-ON Trial in Late 2024 to Early 2025, with Potential NDA Submission on Track for 1H Calendar 2025 Company Anticipates Completion of Pa
Acasti Announces Year-End 2024 Financial Results, Provides Business Update
08:00am, Friday, 21'st Jun 2024
PRINCETON, N.J., June 21, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel injectable formulation of n
Wall Street Favorites: 3 Penny Stocks With Strong Buy Ratings for June 2024
12:31pm, Tuesday, 18'th Jun 2024
As the main stock indices like the S&P 500 and Nasdaq continue to climb, penny stocks are becoming attractive for those seeking significant returns. Despite their reputation for extreme price fluctuat
Acasti Pharma to Attend BIO International Convention 2024
04:05pm, Tuesday, 28'th May 2024
PRINCETON, N.J., May 28, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel, injectable formulation of nim
The Next Novavax? 3 Biopharma Stocks to Buy Before They Boom
06:45am, Thursday, 23'rd May 2024
Novavax (NASDAQ: NVAX ) stock was among the laggards in the race for the vaccine against COVID-19. Unsurprisingly, NVAX stock plunged from highs of $320 in 2021 to recent lows of $3.5.
Acasti Announces Third Fiscal Quarter 2024 Financial Results and Business Highlights
08:00am, Monday, 12'th Feb 2024
PRINCETON, N.J., Feb. 12, 2024 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha
Acasti Announces Poster Detailing its GTX-104 STRIVE-ON Trial
08:00am, Thursday, 01'st Feb 2024
Accepted for Presentation at the 2024 International Stroke Conference Accepted for Presentation at the 2024 International Stroke Conference
Acasti to Participate in Upcoming San Francisco Investor Conferences in January 2024
08:00am, Wednesday, 13'th Dec 2023
PRINCETON, N.J., Dec. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel intravenous formulation of ni
Acasti Announces Second Quarter 2024 Financial Results and Business Highlights
08:00am, Monday, 13'th Nov 2023
PRINCETON, N.J., Nov. 13, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha
Acasti Announces Dosing of First Patient in GTX-104 STRIVE-ON Trial
08:00am, Monday, 23'rd Oct 2023
PRINCETON, N.J., Oct. 23, 2023 (GLOBE NEWSWIRE) -- Acasti Pharma Inc. (Nasdaq: ACST) (Acasti or the Company), a late-stage, biopharma company advancing GTX-104, its novel formulation of nimodipine tha
